hotspot -WSS

hotspot

author：leisure time 2025-09-30 09:31:10 - browse：2

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Unmasking the 'centricity' illusion in clinical trials

entertainment

WSS

Asahi Kasei to buy Calliditas, picking up kidney disease drug

When prostate cancer spreads, where it goes matters

NVIDIA and Google execs on the future of AI and drug discovery

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Readers respond to H5N1 and livestock movements, and more

The Bio Revolution is changing business and society

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Apple is now the first public company to be valued at $3 trillion

NVIDIA and Google execs on the future of AI and drug discovery

23andMe had bad news about my health. I wish a person had delivered it

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

23andMe had bad news about my health. I wish a person had delivered it

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

How to save PrEP access — and even expand it

Bird flu makes raw milk dangerous to consume, mouse study finds

United colonoscopy coverage change 'may cost lives,' doctors say

J&J reports mixed data on next

leisure time

Should insurance cover cosmetic surgery?

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Solving academic medical centers' existential crisis

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

leisure time

entertainment

entertainment

knowledge